The University of Chicago Header Logo

Connection

Mark J. Ratain to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Mark J. Ratain has written about Antibodies, Monoclonal, Humanized.
Mark J. Ratain
Connection Strength
3.098
Antibodies, Monoclonal, Humanized
  1. Subcutaneous Atezolizumab: A Jab Without a Benefit. Clin Pharmacol Drug Dev. 2022 01; 11(1):134-135.
    View in: PubMed
    Score: 0.559
  2. Dose Optimization of Pembrolizumab: Less May Be More. Clin Pharmacol Ther. 2022 05; 111(5):993.
    View in: PubMed
    Score: 0.556
  3. Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19. Clin Pharmacol Ther. 2020 09; 108(3):425-427.
    View in: PubMed
    Score: 0.504
  4. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
    View in: PubMed
    Score: 0.265
  5. Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues? Eur J Cancer. 2023 11; 194:113349.
    View in: PubMed
    Score: 0.158
  6. In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation. J Clin Pharmacol. 2023 06; 63(6):672-680.
    View in: PubMed
    Score: 0.151
  7. Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. J Clin Pharmacol. 2022 04; 62(4):532-540.
    View in: PubMed
    Score: 0.140
  8. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696.
    View in: PubMed
    Score: 0.130
  9. Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. JAMA Oncol. 2020 11 01; 6(11):1694-1695.
    View in: PubMed
    Score: 0.129
  10. Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Letter. Clin Cancer Res. 2020 05 15; 26(10):2435.
    View in: PubMed
    Score: 0.125
  11. Alternative dosing regimens for atezolizumab: right dose, wrong frequency. Cancer Chemother Pharmacol. 2019 12; 84(6):1153-1155.
    View in: PubMed
    Score: 0.120
  12. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
    View in: PubMed
    Score: 0.107
  13. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 01; 10(13):4363-8.
    View in: PubMed
    Score: 0.042
  14. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27.
    View in: PubMed
    Score: 0.037
  15. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer. 2015 Apr 01; 121(7):1025-31.
    View in: PubMed
    Score: 0.021
  16. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15; 20(6):1666-75.
    View in: PubMed
    Score: 0.020
  17. Unsupported off-label chemotherapy in metastatic colon cancer. BMC Health Serv Res. 2012 Dec 29; 12:481.
    View in: PubMed
    Score: 0.019
  18. Vascular endothelial growth factor pathway. Pharmacogenet Genomics. 2010 May; 20(5):346-9.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.